Liraglutide price drop by 20% by end of 2024? | Binary | | | 6 months ago | |
Teva generic liraglutide 10% market share by end of 2024? | Binary | | | 6 months ago | |
Novo Nordisk lawsuit against Teva by March 31, 2025? | Binary | | | 6 months ago | |
Will Liraglutide (Victoza) enter Phase 3 clinical trials for Alzheimer's by end of 2024? | Binary | | | 5 months ago | |
Will FDA grant Fast Track designation to Liraglutide (Victoza) for Alzheimer's treatment by end of 2024? | Binary | | | 5 months ago | |
Teva generic liraglutide market share in diabetes treatment by end of 2024 | Categorical | | | 6 months ago | |
Number of additional generic GLP-1 drugs approved by FDA by June 30, 2025 | Categorical | | | 6 months ago | |
Average price reduction of liraglutide by end of 2024 | Categorical | | | 6 months ago | |
What will be the regulatory approval status of Liraglutide (Victoza) for Alzheimer's treatment by end of 2026? | Categorical | | | 5 months ago | |
Will Novo Nordisk publish Phase 3 trial results for Liraglutide (Victoza) in a peer-reviewed journal by end of 2025? | Binary | | | 5 months ago | |
How will Novo Nordisk's stock price react within one week of Phase 3 trial results for Liraglutide (Victoza) in Alzheimer's treatment? | Categorical | | | 5 months ago | |
What will be the outcome of Phase 3 clinical trials for Liraglutide (Victoza) in Alzheimer's treatment by end of 2025? | Categorical | | | 5 months ago | |
